Neurometabolic Disorders Market, Global Outlook and Forecast 2022-2028

April 2022 | 103 pages | ID: N65C37B396A8EN
Market Monitor Global

Abstracts

Neurometabolic disorders are genetic disorders that disrupt how the body uses or produces energy from food. When this happens, there may be too much of some chemicals (energy from food) or too little of others that are needed to stay healthy.

This report contains market size and forecasts of Neurometabolic Disorders in Global, including the following market information:

Global Neurometabolic Disorders Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Neurometabolic Disorders market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Gaucher’s Disease Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Neurometabolic Disorders include Amicus Therapeutics, ISU Abxis, JCR Pharmaceuticals, Biosidus, Greenovation Biotech, UAB Proforma, Dong-A Socio Group, ExSAR Corporation and Lixte Biotechnology, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Neurometabolic Disorders companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Neurometabolic Disorders Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Neurometabolic Disorders Market Segment Percentages, by Type, 2021 (%)

• Gaucher’s Disease
• Fabry Disease
• Pompe Disease
• Mucopolysaccharidosis VI
• Other

Global Neurometabolic Disorders Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Neurometabolic Disorders Market Segment Percentages, by Application, 2021 (%)

• Oral
• Parenteral

Global Neurometabolic Disorders Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Neurometabolic Disorders Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Neurometabolic Disorders revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Neurometabolic Disorders revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Amicus Therapeutics
• ISU Abxis
• JCR Pharmaceuticals
• Biosidus
• Greenovation Biotech
• UAB Proforma
• Dong-A Socio Group
• ExSAR Corporation
• Lixte Biotechnology
• Neuraltus Pharmaceuticals
• Protalix
• Pharming Group
• Protalix BioTherapeutics
• Amicus
• Biomarin
• Genzyme
• Shire
• Greencross

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Neurometabolic Disorders Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Neurometabolic Disorders Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL NEUROMETABOLIC DISORDERS OVERALL MARKET SIZE

2.1 Global Neurometabolic Disorders Market Size: 2021 VS 2028
2.2 Global Neurometabolic Disorders Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Neurometabolic Disorders Players in Global Market
3.2 Top Global Neurometabolic Disorders Companies Ranked by Revenue
3.3 Global Neurometabolic Disorders Revenue by Companies
3.4 Top 3 and Top 5 Neurometabolic Disorders Companies in Global Market, by Revenue in 2021
3.5 Global Companies Neurometabolic Disorders Product Type
3.6 Tier 1, Tier 2 and Tier 3 Neurometabolic Disorders Players in Global Market
  3.6.1 List of Global Tier 1 Neurometabolic Disorders Companies
  3.6.2 List of Global Tier 2 and Tier 3 Neurometabolic Disorders Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Neurometabolic Disorders Market Size Markets, 2021 & 2028
  4.1.2 Gaucher’s Disease
  4.1.3 Fabry Disease
  4.1.4 Pompe Disease
  4.1.5 Mucopolysaccharidosis VI
  4.1.6 Other
4.2 By Type - Global Neurometabolic Disorders Revenue & Forecasts
  4.2.1 By Type - Global Neurometabolic Disorders Revenue, 2017-2022
  4.2.2 By Type - Global Neurometabolic Disorders Revenue, 2023-2028
  4.2.3 By Type - Global Neurometabolic Disorders Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Neurometabolic Disorders Market Size, 2021 & 2028
  5.1.2 Oral
  5.1.3 Parenteral
5.2 By Application - Global Neurometabolic Disorders Revenue & Forecasts
  5.2.1 By Application - Global Neurometabolic Disorders Revenue, 2017-2022
  5.2.2 By Application - Global Neurometabolic Disorders Revenue, 2023-2028
  5.2.3 By Application - Global Neurometabolic Disorders Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Neurometabolic Disorders Market Size, 2021 & 2028
6.2 By Region - Global Neurometabolic Disorders Revenue & Forecasts
  6.2.1 By Region - Global Neurometabolic Disorders Revenue, 2017-2022
  6.2.2 By Region - Global Neurometabolic Disorders Revenue, 2023-2028
  6.2.3 By Region - Global Neurometabolic Disorders Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Neurometabolic Disorders Revenue, 2017-2028
  6.3.2 US Neurometabolic Disorders Market Size, 2017-2028
  6.3.3 Canada Neurometabolic Disorders Market Size, 2017-2028
  6.3.4 Mexico Neurometabolic Disorders Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Neurometabolic Disorders Revenue, 2017-2028
  6.4.2 Germany Neurometabolic Disorders Market Size, 2017-2028
  6.4.3 France Neurometabolic Disorders Market Size, 2017-2028
  6.4.4 U.K. Neurometabolic Disorders Market Size, 2017-2028
  6.4.5 Italy Neurometabolic Disorders Market Size, 2017-2028
  6.4.6 Russia Neurometabolic Disorders Market Size, 2017-2028
  6.4.7 Nordic Countries Neurometabolic Disorders Market Size, 2017-2028
  6.4.8 Benelux Neurometabolic Disorders Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Neurometabolic Disorders Revenue, 2017-2028
  6.5.2 China Neurometabolic Disorders Market Size, 2017-2028
  6.5.3 Japan Neurometabolic Disorders Market Size, 2017-2028
  6.5.4 South Korea Neurometabolic Disorders Market Size, 2017-2028
  6.5.5 Southeast Asia Neurometabolic Disorders Market Size, 2017-2028
  6.5.6 India Neurometabolic Disorders Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Neurometabolic Disorders Revenue, 2017-2028
  6.6.2 Brazil Neurometabolic Disorders Market Size, 2017-2028
  6.6.3 Argentina Neurometabolic Disorders Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Neurometabolic Disorders Revenue, 2017-2028
  6.7.2 Turkey Neurometabolic Disorders Market Size, 2017-2028
  6.7.3 Israel Neurometabolic Disorders Market Size, 2017-2028
  6.7.4 Saudi Arabia Neurometabolic Disorders Market Size, 2017-2028
  6.7.5 UAE Neurometabolic Disorders Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Amicus Therapeutics
  7.1.1 Amicus Therapeutics Corporate Summary
  7.1.2 Amicus Therapeutics Business Overview
  7.1.3 Amicus Therapeutics Neurometabolic Disorders Major Product Offerings
  7.1.4 Amicus Therapeutics Neurometabolic Disorders Revenue in Global Market (2017-2022)
  7.1.5 Amicus Therapeutics Key News
7.2 ISU Abxis
  7.2.1 ISU Abxis Corporate Summary
  7.2.2 ISU Abxis Business Overview
  7.2.3 ISU Abxis Neurometabolic Disorders Major Product Offerings
  7.2.4 ISU Abxis Neurometabolic Disorders Revenue in Global Market (2017-2022)
  7.2.5 ISU Abxis Key News
7.3 JCR Pharmaceuticals
  7.3.1 JCR Pharmaceuticals Corporate Summary
  7.3.2 JCR Pharmaceuticals Business Overview
  7.3.3 JCR Pharmaceuticals Neurometabolic Disorders Major Product Offerings
  7.3.4 JCR Pharmaceuticals Neurometabolic Disorders Revenue in Global Market (2017-2022)
  7.3.5 JCR Pharmaceuticals Key News
7.4 Biosidus
  7.4.1 Biosidus Corporate Summary
  7.4.2 Biosidus Business Overview
  7.4.3 Biosidus Neurometabolic Disorders Major Product Offerings
  7.4.4 Biosidus Neurometabolic Disorders Revenue in Global Market (2017-2022)
  7.4.5 Biosidus Key News
7.5 Greenovation Biotech
  7.5.1 Greenovation Biotech Corporate Summary
  7.5.2 Greenovation Biotech Business Overview
  7.5.3 Greenovation Biotech Neurometabolic Disorders Major Product Offerings
  7.5.4 Greenovation Biotech Neurometabolic Disorders Revenue in Global Market (2017-2022)
  7.5.5 Greenovation Biotech Key News
7.6 UAB Proforma
  7.6.1 UAB Proforma Corporate Summary
  7.6.2 UAB Proforma Business Overview
  7.6.3 UAB Proforma Neurometabolic Disorders Major Product Offerings
  7.6.4 UAB Proforma Neurometabolic Disorders Revenue in Global Market (2017-2022)
  7.6.5 UAB Proforma Key News
7.7 Dong-A Socio Group
  7.7.1 Dong-A Socio Group Corporate Summary
  7.7.2 Dong-A Socio Group Business Overview
  7.7.3 Dong-A Socio Group Neurometabolic Disorders Major Product Offerings
  7.7.4 Dong-A Socio Group Neurometabolic Disorders Revenue in Global Market (2017-2022)
  7.7.5 Dong-A Socio Group Key News
7.8 ExSAR Corporation
  7.8.1 ExSAR Corporation Corporate Summary
  7.8.2 ExSAR Corporation Business Overview
  7.8.3 ExSAR Corporation Neurometabolic Disorders Major Product Offerings
  7.8.4 ExSAR Corporation Neurometabolic Disorders Revenue in Global Market (2017-2022)
  7.8.5 ExSAR Corporation Key News
7.9 Lixte Biotechnology
  7.9.1 Lixte Biotechnology Corporate Summary
  7.9.2 Lixte Biotechnology Business Overview
  7.9.3 Lixte Biotechnology Neurometabolic Disorders Major Product Offerings
  7.9.4 Lixte Biotechnology Neurometabolic Disorders Revenue in Global Market (2017-2022)
  7.9.5 Lixte Biotechnology Key News
7.10 Neuraltus Pharmaceuticals
  7.10.1 Neuraltus Pharmaceuticals Corporate Summary
  7.10.2 Neuraltus Pharmaceuticals Business Overview
  7.10.3 Neuraltus Pharmaceuticals Neurometabolic Disorders Major Product Offerings
  7.10.4 Neuraltus Pharmaceuticals Neurometabolic Disorders Revenue in Global Market (2017-2022)
  7.10.5 Neuraltus Pharmaceuticals Key News
7.11 Protalix
  7.11.1 Protalix Corporate Summary
  7.11.2 Protalix Business Overview
  7.11.3 Protalix Neurometabolic Disorders Major Product Offerings
  7.11.4 Protalix Neurometabolic Disorders Revenue in Global Market (2017-2022)
  7.11.5 Protalix Key News
7.12 Pharming Group
  7.12.1 Pharming Group Corporate Summary
  7.12.2 Pharming Group Business Overview
  7.12.3 Pharming Group Neurometabolic Disorders Major Product Offerings
  7.12.4 Pharming Group Neurometabolic Disorders Revenue in Global Market (2017-2022)
  7.12.5 Pharming Group Key News
7.13 Protalix BioTherapeutics
  7.13.1 Protalix BioTherapeutics Corporate Summary
  7.13.2 Protalix BioTherapeutics Business Overview
  7.13.3 Protalix BioTherapeutics Neurometabolic Disorders Major Product Offerings
  7.13.4 Protalix BioTherapeutics Neurometabolic Disorders Revenue in Global Market (2017-2022)
  7.13.5 Protalix BioTherapeutics Key News
7.14 Amicus
  7.14.1 Amicus Corporate Summary
  7.14.2 Amicus Business Overview
  7.14.3 Amicus Neurometabolic Disorders Major Product Offerings
  7.14.4 Amicus Neurometabolic Disorders Revenue in Global Market (2017-2022)
  7.14.5 Amicus Key News
7.15 Biomarin
  7.15.1 Biomarin Corporate Summary
  7.15.2 Biomarin Business Overview
  7.15.3 Biomarin Neurometabolic Disorders Major Product Offerings
  7.15.4 Biomarin Neurometabolic Disorders Revenue in Global Market (2017-2022)
  7.15.5 Biomarin Key News
7.16 Genzyme
  7.16.1 Genzyme Corporate Summary
  7.16.2 Genzyme Business Overview
  7.16.3 Genzyme Neurometabolic Disorders Major Product Offerings
  7.16.4 Genzyme Neurometabolic Disorders Revenue in Global Market (2017-2022)
  7.16.5 Genzyme Key News
7.17 Shire
  7.17.1 Shire Corporate Summary
  7.17.2 Shire Business Overview
  7.17.3 Shire Neurometabolic Disorders Major Product Offerings
  7.17.4 Shire Neurometabolic Disorders Revenue in Global Market (2017-2022)
  7.17.5 Shire Key News
7.18 Greencross
  7.18.1 Greencross Corporate Summary
  7.18.2 Greencross Business Overview
  7.18.3 Greencross Neurometabolic Disorders Major Product Offerings
  7.18.4 Greencross Neurometabolic Disorders Revenue in Global Market (2017-2022)
  7.18.5 Greencross Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Neurometabolic Disorders Market Opportunities & Trends in Global Market
Table 2. Neurometabolic Disorders Market Drivers in Global Market
Table 3. Neurometabolic Disorders Market Restraints in Global Market
Table 4. Key Players of Neurometabolic Disorders in Global Market
Table 5. Top Neurometabolic Disorders Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Neurometabolic Disorders Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Neurometabolic Disorders Revenue Share by Companies, 2017-2022
Table 8. Global Companies Neurometabolic Disorders Product Type
Table 9. List of Global Tier 1 Neurometabolic Disorders Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Neurometabolic Disorders Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Neurometabolic Disorders Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Neurometabolic Disorders Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Neurometabolic Disorders Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Neurometabolic Disorders Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Neurometabolic Disorders Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Neurometabolic Disorders Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Neurometabolic Disorders Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Neurometabolic Disorders Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Neurometabolic Disorders Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Neurometabolic Disorders Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Neurometabolic Disorders Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Neurometabolic Disorders Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Neurometabolic Disorders Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Neurometabolic Disorders Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Neurometabolic Disorders Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Neurometabolic Disorders Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Neurometabolic Disorders Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Neurometabolic Disorders Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Neurometabolic Disorders Revenue, (US$, Mn), 2023-2028
Table 30. Amicus Therapeutics Corporate Summary
Table 31. Amicus Therapeutics Neurometabolic Disorders Product Offerings
Table 32. Amicus Therapeutics Neurometabolic Disorders Revenue (US$, Mn), (2017-2022)
Table 33. ISU Abxis Corporate Summary
Table 34. ISU Abxis Neurometabolic Disorders Product Offerings
Table 35. ISU Abxis Neurometabolic Disorders Revenue (US$, Mn), (2017-2022)
Table 36. JCR Pharmaceuticals Corporate Summary
Table 37. JCR Pharmaceuticals Neurometabolic Disorders Product Offerings
Table 38. JCR Pharmaceuticals Neurometabolic Disorders Revenue (US$, Mn), (2017-2022)
Table 39. Biosidus Corporate Summary
Table 40. Biosidus Neurometabolic Disorders Product Offerings
Table 41. Biosidus Neurometabolic Disorders Revenue (US$, Mn), (2017-2022)
Table 42. Greenovation Biotech Corporate Summary
Table 43. Greenovation Biotech Neurometabolic Disorders Product Offerings
Table 44. Greenovation Biotech Neurometabolic Disorders Revenue (US$, Mn), (2017-2022)
Table 45. UAB Proforma Corporate Summary
Table 46. UAB Proforma Neurometabolic Disorders Product Offerings
Table 47. UAB Proforma Neurometabolic Disorders Revenue (US$, Mn), (2017-2022)
Table 48. Dong-A Socio Group Corporate Summary
Table 49. Dong-A Socio Group Neurometabolic Disorders Product Offerings
Table 50. Dong-A Socio Group Neurometabolic Disorders Revenue (US$, Mn), (2017-2022)
Table 51. ExSAR Corporation Corporate Summary
Table 52. ExSAR Corporation Neurometabolic Disorders Product Offerings
Table 53. ExSAR Corporation Neurometabolic Disorders Revenue (US$, Mn), (2017-2022)
Table 54. Lixte Biotechnology Corporate Summary
Table 55. Lixte Biotechnology Neurometabolic Disorders Product Offerings
Table 56. Lixte Biotechnology Neurometabolic Disorders Revenue (US$, Mn), (2017-2022)
Table 57. Neuraltus Pharmaceuticals Corporate Summary
Table 58. Neuraltus Pharmaceuticals Neurometabolic Disorders Product Offerings
Table 59. Neuraltus Pharmaceuticals Neurometabolic Disorders Revenue (US$, Mn), (2017-2022)
Table 60. Protalix Corporate Summary
Table 61. Protalix Neurometabolic Disorders Product Offerings
Table 62. Protalix Neurometabolic Disorders Revenue (US$, Mn), (2017-2022)
Table 63. Pharming Group Corporate Summary
Table 64. Pharming Group Neurometabolic Disorders Product Offerings
Table 65. Pharming Group Neurometabolic Disorders Revenue (US$, Mn), (2017-2022)
Table 66. Protalix BioTherapeutics Corporate Summary
Table 67. Protalix BioTherapeutics Neurometabolic Disorders Product Offerings
Table 68. Protalix BioTherapeutics Neurometabolic Disorders Revenue (US$, Mn), (2017-2022)
Table 69. Amicus Corporate Summary
Table 70. Amicus Neurometabolic Disorders Product Offerings
Table 71. Amicus Neurometabolic Disorders Revenue (US$, Mn), (2017-2022)
Table 72. Biomarin Corporate Summary
Table 73. Biomarin Neurometabolic Disorders Product Offerings
Table 74. Biomarin Neurometabolic Disorders Revenue (US$, Mn), (2017-2022)
Table 75. Genzyme Corporate Summary
Table 76. Genzyme Neurometabolic Disorders Product Offerings
Table 77. Genzyme Neurometabolic Disorders Revenue (US$, Mn), (2017-2022)
Table 78. Shire Corporate Summary
Table 79. Shire Neurometabolic Disorders Product Offerings
Table 80. Shire Neurometabolic Disorders Revenue (US$, Mn), (2017-2022)
Table 81. Greencross Corporate Summary
Table 82. Greencross Neurometabolic Disorders Product Offerings
Table 83. Greencross Neurometabolic Disorders Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Neurometabolic Disorders Segment by Type in 2021
Figure 2. Neurometabolic Disorders Segment by Application in 2021
Figure 3. Global Neurometabolic Disorders Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Neurometabolic Disorders Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Neurometabolic Disorders Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Neurometabolic Disorders Revenue in 2021
Figure 8. By Type - Global Neurometabolic Disorders Revenue Market Share, 2017-2028
Figure 9. By Application - Global Neurometabolic Disorders Revenue Market Share, 2017-2028
Figure 10. By Region - Global Neurometabolic Disorders Revenue Market Share, 2017-2028
Figure 11. By Country - North America Neurometabolic Disorders Revenue Market Share, 2017-2028
Figure 12. US Neurometabolic Disorders Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Neurometabolic Disorders Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Neurometabolic Disorders Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Neurometabolic Disorders Revenue Market Share, 2017-2028
Figure 16. Germany Neurometabolic Disorders Revenue, (US$, Mn), 2017-2028
Figure 17. France Neurometabolic Disorders Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Neurometabolic Disorders Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Neurometabolic Disorders Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Neurometabolic Disorders Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Neurometabolic Disorders Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Neurometabolic Disorders Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Neurometabolic Disorders Revenue Market Share, 2017-2028
Figure 24. China Neurometabolic Disorders Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Neurometabolic Disorders Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Neurometabolic Disorders Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Neurometabolic Disorders Revenue, (US$, Mn), 2017-2028
Figure 28. India Neurometabolic Disorders Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Neurometabolic Disorders Revenue Market Share, 2017-2028
Figure 30. Brazil Neurometabolic Disorders Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Neurometabolic Disorders Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Neurometabolic Disorders Revenue Market Share, 2017-2028
Figure 33. Turkey Neurometabolic Disorders Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Neurometabolic Disorders Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Neurometabolic Disorders Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Neurometabolic Disorders Revenue, (US$, Mn), 2017-2028
Figure 37. Amicus Therapeutics Neurometabolic Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. ISU Abxis Neurometabolic Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. JCR Pharmaceuticals Neurometabolic Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Biosidus Neurometabolic Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Greenovation Biotech Neurometabolic Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. UAB Proforma Neurometabolic Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Dong-A Socio Group Neurometabolic Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. ExSAR Corporation Neurometabolic Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Lixte Biotechnology Neurometabolic Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Neuraltus Pharmaceuticals Neurometabolic Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Protalix Neurometabolic Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Pharming Group Neurometabolic Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Protalix BioTherapeutics Neurometabolic Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Amicus Neurometabolic Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. Biomarin Neurometabolic Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 52. Genzyme Neurometabolic Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 53. Shire Neurometabolic Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 54. Greencross Neurometabolic Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)